La Thangue NB et al. Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011;8(10):587-96. Abstract

Love N et al. Is adjuvant oxaliplatin (Ox) overutilized in colon cancer (CC)? 408 cases from the practices of 102 oncologists. Gastrointestinal Cancers Symposium 2013;Abstract 479.

Roth AD et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104(21):1635-46. Abstract

Salazar R et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011;29(1):17-24. Abstract

Sargent D et al. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 2011;47(7):990-6. Abstract

Schmoll HJ et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23(10):2479-516. Abstract

Tournigand C et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30 (27):3353-60. Abstract

Yothers G et al. Validation of the 12-gene colon cancer Recurrence Score in NSABP C-07 as a predictor of recurrence in patients with Stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol 2013;[Epub ahead of print]. Abstract